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RIASSUNTO 
 
La Medicina di Genere è una nuova dimensione della Medicina nata negli USA negli 
anni ’90, quando l’OMS incluse un capitolo sull’Health Equity con il XXI Century 
Program. 
Nasce come necessità di prevenzione e cura mirate per le malattie dell’uomo e della 
donna. Basti pensare agli studi clinici di tante malattie che colpiscono entrambi i 
sessi (es., le malattie cardiovascolari), ma che prevalentemente continuano ad 
arruolare gli uomini, o a patologie chiamate di genere femminile, come l’osteoporosi 
e il cancro alla mammella, che colpiscono anche la popolazione maschile. 
Sulla base di tale premessa, l’obbiettivo iniziale della ricerca è stato quello di 
descrivere la storia prescrittiva di tutti i farmaci nell’anno 2010. Tramite l’analisi dei 
dati di prescrizione provenienti dall’Assistenza Farmaceutica Territoriale di Padova è 
stato possibile descrivere l’utilizzo di questi farmaci nella popolazione generale. 
Sono risultati maggiormente utilizzati: gli antibiotici (con 39% M vs 46 % F con 
almeno un antibiotico prescritto, p<0,001), gli antiulcera( 13,20% M vs 16,68 % F, 
p<0,001), gli antireumatici (10,84% M vs 16,70 % F, p<0,001), gli antidepressivi 
(con 3,74% M vs 8,09 % F, p<0,001) etc., con una prevalenza di trattati del genere 
femminile. Una prevalenza di trattati del genere maschile è stata osservata  invece 
per gli antitrombotici (con 12,11% M vs 11,33% F, p<0,025), gli antidiabetici di cui 
insulino-trattati 1,26% M vs 1,03 % F, p<0,05 ed i trattati con ipoglicemizzanti 3,73% 
M vs 2,83 % F, p<0,05) ed i dislipidemici (8,93%M vs 8,08%F, p<0,025) etc. Tutti 
questi dati riportati sono statisticamente significativi. Questa analisi indica anche che 
il genere femminile è in assoluto il maggior consumatore di farmaci antidolorifici, 
risultato che porta a dedurre che le donne soffrono maggiormente di dolore acuto e 
cronico, ma può essere anche un indicatore di una maggiore propensione della 
donna alla ricerca di una visita medica rispetto all’uomo, il quale forse preferisce 
rimedi autogestibili (OTC oppure a fumo e alcool). L’alto numero di donne fra i 
 trattati con farmaci del sistema nervoso (antipsicotici, antidepressivi) fa pensare a 
questi “giorni moderni” in cui la donna è ancora vittima di violenza non solo fisica, 
ma anche psichica, e si trova spesso sottoposta a stress, come risultato 
dell’emancipazione. La  moglie-madre-donna in carriera è esposta ad una vita 
frenetica e le tante responsabilità accumulate negli anni tendono a portarla alla 
parità col genere maschile.  
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Una analisi più approfondita è stata fatta nello specifico per i farmaci 
cardiovascolari. La maggior parte dei farmaci cardiovascolari è stato dispensato 
prevalentemente al genere maschile, ma bisogna sottolineare che le malattie 
cardiovascolari erano la causa principale di morte in entrambi i sessi. Non si è 
verificata alcuna differenza di genere nella prevalenza di trattati per i sottogruppi dei 
betabloccanti non associati, calcio antagonisti con effetto cardio-diretto e antagonisti 
dell’angiotensina II, mentre per gli antitrombotici, gli antiaritmici di classe sia I che III, 
gli ipocolesterolemizzanti e ipotrigliceridemizzanti si è osservato un utilizzo 
maggiore nel genere maschile. 
Per quanto riguarda le malattie trombotiche, le femmine risultavano meno trattate 
dei maschi, in accordo con il fatto che il maschio adulto, a parità di età, è più 
propenso alla trombosi rispetto alla femmina adulta, perché con l’avanzare dell’età 
ha una maggiore aggregazione piastrinica rispetto alla femmina.  
 Infine, l’attenzione è stata focalizzata sull’evento della sindrome coronarica acuta 
(SCA) per analizzare la presenza di eventuali differenze di genere in pazienti 
ospedalizzati per SCA in relazione ai seguenti indicatori: prevalenza di ricoveri per 
SCA, mortalità intra- ed extra-ospedaliera, tipologia di interventi di 
rivascolarizzazione, trattamento farmacologico alla dimissione, aderenza alla terapia 
e sopravivvenza. 
Nel corso dell’anno 2008, sono stati ricoverati per SCA 1.204 pazienti (760 maschi  
e 444 femmine). La prevalenza dei ricoveri è stata significativamente superiore negli 
uomini (3,26‰ ) rispetto alle donne (0,92‰) con OR = 1,7 (IC 95% = 1,4-2,0). Dei 
1.204 pazienti arruolati 142, ovvero 11,8%, sono andati incontro a decesso 
intraospedaliero.  Sono state analizzate le recidive a breve e lungo termine. Le 
donne in entrambi i casi andavano in contro a recidive più frequentemente degli 
uomini (nel 2009 il 17,9% delle donne vs. 12,6% degli uomini e nel 2012 32% donne 
vs. 24% degli uomini, p<0,05). Una fotografia della terapia nei 12 mesi precedenti 
l’evento evidenziava un trattamento con antiipertensivi e antidepressivi maggiore 
nelle donne. Per quanto riguarda il trattamento del diabete e delle dislipidemie non 
si evidenzia nessuna differenza di genere nell’utilizzo dei farmaci riguardanti queste 
patologie. E‘ stata fatta una analisi degli interventi di rivascolarizzazione per rilevare 
eventuali differenze di genere e differenze di età. Il 40,12% della popolazione è 
andata incontro a rivascolarizzazione invece il 48,1% non è stata rivascolarizzata. 
Nella fascia di età 65-79 anni il 73,4% dei maschi ha subito un intervento di 
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rivascolarizzazione contro il 26,6% delle donne (OR=1,7 con IC 95% =1,2-2,5). 
Negli over 80, gli uomini sono sempre maggiormente rivascolarizzati (71,2%M vs 
28,8F OR= 4,1 con IC 95% = 2,2-7,6). Questi dati hanno confermato che in 
generale gli uomini vengono sottoposti a questo tipo di interventi più delle donne. 
Per quanto riguarda l'aderenza alla terapia, i pazienti di sesso maschile sono stati 
più aderenti alla terapia limitatamente all’aspirina (92% M vs 82% F, OR = 2,4 IC 
95% 1,2-4,6). L'analisi di sopravvivenza ha mostrato una prognosi migliore del 
genere maschile, con una mortalità più alta del genere femminile. 
Merita porre l’accento sul fatto che in questi anni l’utilizzo di farmaci cardiovascolari 
da parte delle donne sta aumentando. La donna è sempre più esposta a rischi come 
fumo, alcool, condizioni di malessere che la portano alla ricerca di farmaci e a volte 
è esposta a politerapie poco controllate, che aumentano il rischio di reazioni 
avverse. Conseguenti costi inutili potrebbero essere evitati se ci fosse una terapia 
adeguata per genere ed età (soprattutto per gli anziani maggiormente soggetti a 
malattie croniche). Nasce così l’importanza di una cura appropriata della condizione 
di malessere o di malattia. La società di oggi si sta evolvendo verso abitudini 
sempre più consumiste, abusi di sostanze come fumo, alcol, droga da parte di 
entrambi i generi. Nasce così l’esigenza di agire in modo coerente in termini 
d’informazione del cittadino (assistibile/assistito) e di indurre una maggiore 
consapevolezza nel medico, che possa così mettere in atto una terapia adeguata, 
tenendo conto non solo delle funzioni biologiche e fisio-patologiche del paziente, ma 
anche dell’ambiente socio-culturale e delle differenze di genere! 
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Abstract 
Introduction: It has been clearly evidenced that physiologic differences between 
men and women are numerous regarding every organ and apparatus as for nervous 
system, immune system and especially for cardio-vascular system. Epidemiology is 
of great help in analysing these differences by offering several measures to describe 
therapies outcome as predictors to health/disease patterns. Acute Coronary 
Syndrome (ACS) may occur in both men and women, but with different symptoms, 
risk factors or types at presentation. This leads to different clinical and 
pharmacological management and possibly in the health outcome. 
Objective: The purpose of this analysis was to explore, by using an administrative 
database, gender and age differences in drug prescriptions of ordinarily residents,  
entitled to either free or subsidised approved prescribed drugs and medicines and 
and surgical interventions provided from the Local Health Service. Further analysis 
was performed in the cohort of patients that experienced an ACS during 2008. 
Methods: All residents of the Local Health Service Area 16 of the Veneto Region 
(Italy) ages 15-44, 45-64, 65-79 and >=80 years in the period 1st of January until 31st 
of December 2010, were included in the study. The Local Health Service system, 
covering this area, keeps record of all drug prescriptions dispensed by public or 
private pharmacies. All medications dispensed during 2010 were considered and 
classified according to Anatomical Therapeutic Chemical (ATC) classification 
system. Results were reported as odds ratios (OR) of prescriptions dispensed to 
males and females with 95% confidence intervals (CI) to analyse the number of 
subjects that received at least one medication. A detailed analysis was conducted 
for Cardiovascular drugs (ATC: C) in the cohort of 1,204 ACS patients (760 men and 
444 women) being admitted in Saint’Anthony Hospital. Data of therapies and 
interventions were collected from the hospital and local medical distribution 
database.  
Results: Of the 491,261 included subjects, 255,026 were females and 236,235 
males. Females were medicine dispensed in most of ATC subgroups as with 
antiulcer drugs (OR=0.80, 95% confidence interval [CI] 0.74-0.86), antibiotics(39% 
M vs. 46% F, p<0.001) as for tetracyclines (OR=0.91 95% CI 0.85-0.93), penicillins 
(OR=0.90 in the 95% CI 0.83-0.94), antimigraine preparations (OR 0.34 95% CI 
0.0.31-0.36), antipsychotics (OR=0.86, 95% CI 0.81-0.90), antidepressants 
(3.74%M vs. 8.09% F, OR=0.44, 95% CI 0.40-0.52) diuretics (OR=0.72, 95% CI 
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0.66-0.80). On the other hand, males were dispensed more  with antidiabetic drugs, 
insulin therapy (OR= 1.24 95% CI 1.21-1.30) and with oral hypoglycaemic (OR=1.37 
95% CI 1.33-1.40), more exposed to treatment for cardiovascular disease with 
antithrombotic agents (12.11% M vs. 11.33%F, OR=1.16 95% CI 1.14-1.20), 
betablockers (OR=1.15 95% CI 1.10-1.20), ACE-inhibitors (OR=1.25 95% CI 1.20-
1.30). Males were generally more prescribed with cardiovascular medications than 
their female counterparts. An obvious gender difference in drug utilisation was 
noticed during the 15-44 years of age, this difference decreased with aging, but still 
the medication use difference remained statistically significant.   
 The prevalence of ACS was 2.5 ‰ (3.26‰ in male patients and 0.92‰ in female 
patients, OR=1.7 95% CI 1.4-2.0). Of the ACS patients, 142 (11.8%) died in hospital 
without any gender and age difference. Thus, for further investigations a cohort of 
1,062 ACS patients (688 male and 374 female patients) was considered. Of these 
patients 40.12% underwent a revascularization intervention and 48.1% were not 
revascularised. Male patients over 65 years of age (73.4%) were significantly more 
likely to have a revascularization than the female patients (26.6%) of the same age 
(age group: 65-79, OR=1.7 95%CI 1.2-2.5; age group >=80, OR=4.1 95%CI 2.2-
7.6).  
Six months after hospital discharge antiaggregation therapy was analysed. In the 
ACS population 82% received at least one antiaggregant. The remaining population 
18% did not receive any antiaggregant at all, generally those were female patients 
(OR=2.8 95%CI 2.1-3.8). 
 Aspirin was used in 35% of the non- revascularized vs. 28 % of the revascularized 
patient especially in non-revascularized female patients; Thienopyridines were 
dispensed in 8% of the non-revascularized vs. 5% of the revascularized patients 
especially in revascularized female patients, dual antiplateletes therapy was more 
dispensed in revascularized patients (61% vs. 29%), especially in male non-
revascularized patients. For the other non mentioned therapies male and female 
patients were treated equally.  
Regarding to therapy adherence, male patients were in general more adherent to 
Aspirin (92%M vs. 82%F, OR=2.4 95%CI 1.2-4.6) on the other hand, to 
Thienopyridines (87%M vs. 84%F, OR=1.3 95%CI 0.3-5.0) and to Dual-
antiplateletes therapy (76%M vs.74%F, OR=1.1 95%CI 0.7-1.8) both male and 
female patients were adherent without gender differences. 
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Conclusions: As women are more exposed to chronic and acute conditions, 
especially in the reproductive years 15 to 44 and in pre- and post-menopausal age, 
according to the literature, our results support the suggestion that females are 
dispensed more medicines  than males in general. On the contrary, men were more 
exposed to cardiovascular drugs than women. ACS occured more frequently in men 
than in women. In general men were more revascularized than women.  
On discharge, female patients were not usually treated with antiaggregant therapy, 
more often than their male counterparts. Revascularized patients compared to non-
revascularized patients did not have any gender difference in terms of therapy, but 
an evaluation between non-revascularized patients indicated an inequity between 
male-female patients use of antiaggregants. On the whole, both female and male 
ACS patients were adherent to therapy. In general, men had a better survival than 
women. 
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1 Introduction 
A new dimension of medicine was stressed in the 90‘s, when WHO included in the 
XXI century Program the Health Equity chapter. It was stressed that women die from 
the same disease as men (e.g. heart disease, cancer and stroke), but women were 
not being enrolled in clinical studies. In Europe women live on average 6 years 
longer than men showing a difference in life expectancy, but living longer doesn’t 
mean living better and healthy. Gender differences  were noticed in morbidity and 
mortality anyway females were disqualified routinely from all medical researches. It 
has been clearly evidenced that physiologic differences between men and women 
are numerous regarding every organ and apparatus as for cardio-vascular system, 
nervous system and immune system. These differences affect drug efficacy and 
safety including pharmacokinetic and pharmacodynamic aspects.  
The purpose of the present analysis was to explore , possible gender differences in 
drug prescriptions, utilizing an administrative database. Different studies reported 
that women were prescribed more drugs for all conditions and disease, except for 
cardiovascular disease. In addition, women were less adherent to therapies. 
Cardiovascular disease is the primary cause of death worldwide. Women think that 
cancer is the most dangerous disease and take more prevention cares to it. Instead 
they should think also about cardiovascular disease and undergo periodic heart 
checkups especially during post-menopause. This underconsideration makes 
women less prone to seek cardiac prevention and care. Even physicians 
underdiagnose and undertreat female patients in their first heart-coronary problems. 
Usually, specific symptoms are not recognised thus treatment may be delayed.  
 According to the present analysis further investigation was done in a cohort of 
patients that experienced acute coronary syndrome and results were compared  to 
th region population (Osmed, 2012) as our ACS patients (Saint’Anthony hospital) 
are a sub-population of the ARNO report (Veneto Region).    
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2 Review of the literature 
2.1 Concepts of sex and gender in healthcare 
In the latest years, an important factor that influences individual health and 
healthcare other then sex and age was shown to be the gender difference. 
This factor has been neglected when in a variety of preclinical and clinical studies  
the male animals and men were used. It has been, thus important to consider other 
variables that can influence extremely male and female in prevention, healing and 
care. 
Sex differences are related to biology: genetics, anatomy and physiology. Gender 
refers to socio-cultural phenomena related to rules, traditions and social 
relationships in cultures shaping the feminine and masculine behaviour. It is a 
complexity of norms, relations and individual identity. Gender norms consider the 
appropriate behaviour of men and women, gender relations evaluate the actual roles 
of individuals (men and women) in any one society, and the identity is the way that 
individuals (men and women) introduce themselves and are perceived by others 
(Gendered Innovations, 2013). 
Sex and gender are analytically distinct but not independent. They interrelate in 
important and multifaceted ways: “Not only can gender relations influence 
expression and interpretation of biological traits, but also sex-linked biological 
characteristics can, in some cases, contribute to or amplify gender differentials in 
health” (Krieger, 2003). 
 
2.2 Gender differences in therapies 
There are sex-gender differences with regard to the prevention, epidemiology, 
evolution prognosis, therapy and outcome of diseases. Medications are used to treat 
morbidity, especially in older ages, but also to prevent health-related disorders 
among healthy individuals (Nilsson, 2006).   
Therapies are mostly developed in males. Protective pathways in females are not 
well analyzed. Some of the drugs effective in males are not meant to be effective in 
females, too (Regitz-Zagrosek, 2006). Thus, therapies for patients with the same 
pathology are not the same (in terms of doses, gender related pharmacokinetic, 
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pharmacodynamic and effectiveness or kind of medications). In pharmacokinetics of 
drug administration, metabolism, absorption, distribution and elimination gender 
differences were observed, especially in activity of drug metabolizing enzymes and, 
to a less extent, for absorption. For example, the metabolisation is a process 
occurred in many drugs by enzymes of the cytochrome p450 (CYP) system. 
Hormones, including estrogens and progestins are metabolized via these enzymes. 
Women seem to have a higher clearance of CYP3A4 substrates, although findings 
are not consistent. Menstrual cycle, pregnancy and menopause can be associated 
with changes in pharmacokinetics, because of sex steroid concentrations and 
alteration of body water. In pharmacodynamics an there is an important relation 
between receptors and sex hormones (estrogens) which can modulate the 
regulation of receptors in heart, vessels etc, (e.g beta-adrenergic receptors and 
cardiovascular medications: estrogen deficiency up-regulate beta1 receptors, 
showing a good activity of beta blockers in men) (Jochamann et al., 2005). Another 
example of hormone influence was observed for estrogens and androgens in the 
immune reactivity. Estrogens induce inflammation; on the other hand androgens 
show anti-inflammatory effect. Immune reactivity is significantly higher in women, 
thus they use more anti-inflammatory drugs, also they perceive more pain and 
require higher doses of opioid analgesics (morphine) (Cepeda et al., 2003). Another 
study reported the connection between migraines and estrogen levels in women 
(Cornforth et al., 2009).  
Physical abuse or sexual abuse and psychic abuse appear to be related to pain and 
mood disorders in women. Differences in therapies are related to sex differences as 
chromosomes, genes and hormones but also there is another social and 
environment impact. Women have larger number of comorbid pain conditions as 
depression and anxiety related to effects of living arrangements, employment 
history, social support, marital status and family composition (Greenspan et al., 
2007).  
An important determinant for greater dispensing medications to one gender as 
compared to the other is the behaviour of health seeking. Women are more likely to 
visit a physician than men. They discuss easier any kind of disorder. They report a 
higher grade of abdominal pain (Labus et al., 2008), or heartburn (Oliveria et al., 
1999) and a higher frequency of migraine (Lipton et al., 2005). 
                                                           2 Review of the literature 
 
  
 
  4 
 
In drug-prescribing some gender-related differences among physicians were 
noticed. If the physician was a male, hypertensive female patients resulted to be 
undertreated (Journath et al., 2008). 
Compliance and adherence to therapy are very important. Better adherence is 
associated with better prognosis, survival and lower risk of hospitalization, especially 
in chronic diseases (Wu et al., 2006). To understand the reason associated with 
adherence may provide opportunities for intervention. Different studies reported 
conflictual results as women are the less adherent, or no gender difference in 
adherence to therapies were observed. 
Another study (Dunbar-Jacob, 2002) reported that women, especially those under 
75, are less adherent than men, and they are more likely to over-report adherence. 
Factors that may contribute to poor medication adherence are depression, cognitive 
impairment, social support, severity of illness (Brossworth et al., 2008; Stilley et al., 
2004) etc. Most of psycosocial factors are more attributed to women. Smoke and 
alcohol abuse are associated with a poor medical adherence (Evangelista et al., 
2001). 
 
2.3 Cardiovascular system and gender 
Cardiovascular disease remains the primary cause of death worldwide but age of 
onset, severity and fatalities differ between women and men. The number of women 
participating in studies on cardiovascular disease has increased since mid-1980s. 
However, physiological and molecular bases of differences between women and 
men which contribute to development of cardiovascular disease and response to 
therapy remain underexplored. Women are still under represented in trials as for 
arterial hypertension and heart failure (Stramba-Badiale, 2010). Women frequently 
respond in a different way from men to many cardiovascular medications as a result 
of different physiology, pharmacokinetics and pharmacodynamics. 
Physiologic differences include smaller heart, larger proportion of body fat, lower 
glomerular filtration rate etc., observed in women. The complement of sex 
chromosomes and the influence of hormones affect all components of the vascular 
wall, the heart and autonomic nervous system. Sex and hormones, for example the 
menstrual cycle, menopause and pregnancy, fluctuate during those cycles and this 
can influence plasma levels of cardiovascular drugs as well as vascular healing and 
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development of atheroma which involve activation (or suppression) of blood 
elements including those of the immune system (Miller, 2008). Inflammation is an 
important prognostic indicator in women. “Basic science studies of the 
cardiovascular system must identify experimental material including species/strain 
characteristics, sex and hormonal status including the presence of gonadal steroids 
at the time of testing, during development or number of pregnancies” (Miller, 2009). 
There are differences in prevalence, incidence and severity of diseases. Major 
gender differences have been observed in heart failure and its most frequent causes 
hypertension, myocardial infarction, coronary artery disease, cardiomyopathies and 
atrial fibrillation. Hypertension, diabetes and myocardial hypertrophy are major risk 
factors for heart failure in women. There is a heart failure difference between men 
and women, showing that women suffer of diastolic heart failure and men more from 
systolic heart failure. Myocardial infarction is more relevant in men. Other factors 
such as composition of diets, stress due to handling, social interactions and 
disruption of sleep/wake cycles have the potential to impact experimental outcomes. 
Obesity and insulin resistance inhibit myocardial substrate metabolism and 
efficiency in young women. Obesity, hypertension and dyslipidemia are interrelated 
risk factors. They are associated with inflammation in women. Diabetes is a stronger 
risk factor for heart failure in women than in men. Metabolic syndrome has gender 
specific traits (Regitz-Zagrosek, 2007). 
Medication therapies depend on the physician. It was observed that male physicians 
usually undertreat hypertensive women (Journath, 2008). Hypertensive women are 
usually treated with diuretics, hypertensive males are more often treated with Beta-
blockers, Calcium Antagonist channel blockers and ACE-inhibitors. 
Adherence to therapy is another important factor considered. Contrary to popular 
belief fewer medication was associated with lower adherence with chronic 
cardiovascular regimens (Shalansky, 2002), and men were more adherent to 
medication recommendations than females especially for hypertension (Shiah-Liah, 
2011). 
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2.4 Definition of Acute Coronary Syndrome  
Acute Coronary Syndrome (ACS) is a group of clinical conditions occurring when an 
atherotic plaque ruptures leading to thrombus formation within a coronary artery, or 
coronary thrombosis. It is an unstable atherothrombotic coronary disease. First 
symptoms occurring are chest pain and diaphoresis.  
It is important to diagnose the ACS event with measurement of cardiac markers as 
troponins, and ST segment-evaluation on ECG for a better emergency 
management.  ACS patients may experience: 
•  ST-segment elevation Myocardial Infarction (STEMI), the most dangerous 
infarction that occludes completely and steadily. It is observed that the 
coronary cardiac markers become abnormal and there is an elevation of the 
ST segment in the ECG. 
•  without ST-segment elevation of Myocardial Infarction (NSTEMI), it is a less 
dangerous infarction caused by the incomplete and temporary occlusion of 
the coronary. Myocardial biomarkers are higher, but there is not an ST-
segment elevation. 
• Unstable Angina (UA), occurring often at rest. In this case all ACS 
biomarkers and ECG are normal. (Van de Werf, 2008; Bassand, 2007) 
The stable angina is not a type of ACS, because it occurs after an emotion, hard 
activity and does not resolve at rest. (MerckMedicus, 2009) 
ACS is gender and age specific in both symptoms and risk factors at presentation. 
Women tend to present later than men, and usually with atypical symptoms 
(Goldberg, 2000). 
Primary prevention of this disease consists in controlling risk factors as: healthy 
eating, making exercise, treatment for hypertension or diabetes, controlling 
cholesterol levels, and avoiding smoking. As society is in a continuous evolution 
thus starting with primary prevention can make a gender/age difference in ACS 
occurrence. Based on international literature (Saubouret, 2010; Akhter, 2009, Hee 
Tae, 2011), women at presentation are older and have higher rates of comorbidities 
such as diabetes and hypertension. Secondary prevention consists in 
pharmacologic therapy, coronary interventions, and concomitant therapy (Coven, 
2012). There is also evidence that women are less likely to be treated for ACS, and 
even at discharge are less likely to be given aspirin, thienopyridines, beta-blockers 
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and statins. Often are less compliant to therapies (Akhter, 2009). Moreover they 
tend to be less revascularized than men (Sabouret, 2010, Hee Tae, 2011) although 
having higher rates of in-hospital complications, and higher mortality rates among 
young ages (Claassen, 2012). It is obvious that there is a gender difference among 
ACS patients. 
 
3 Objectives 
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3 Objectives  
The objective of this analysis was to explore, by using an administrative database, 
gender and age-related differences in drug prescriptions dispensed by regional 
pharmacies of the National Health Service, Unità Locale Socio Sanitaria, ULSS 16 
of the Italian city, Padua. 
A major importance has been given to medications of the cardiovascular system,  
Further analyses were done in a cohort of patients hospitalized at Saint’Anthony 
hospital following an acute coronary syndrome event during 2008 to investigate 
potential gender/age-related differences in: 
 population-based prevalence on admission 
 in-hospital mortality 
 anti-aggregation therapy and related adherence to it six months after 
discharge 
 coronary interventions (management of revascularization or not) 
 pharmacologic therapy in the 12 months before the ACS event: 
hypertension, diabetes, dyslipidemias and depression treatments were 
considered as possible risk factor predictors 
 short term relapse (1 year after discarge), long term relapse (3 years after 
discharge) and cohort survival rate until 30th of June 2012. 
 
 
 
 
 
 
 
 
 
3 Objectives 
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4 Population and Methods 
4.1 Study design 
This is an observational and retrospective study. The Local Health Sevice (Unità 
Locale Socio Sanitaria ULSS16) is a regional agency that provides care service to 
residents of the Veneto Region in Italy. Data were extracted from ARNO database, 
where all the so called “red prescriptions“ entitled to either free or subsidised from 
the National Health Service (NHS), are registered. The study includes the number of 
individuals (population of ULSS 16) and all medications dispensed over one year. 
Medications were classified by ATC for easier and manageable view of results. 
Further analyses were done for ATC= C, the Cardiovascular System drugs. 
Moreover, as coronary heart disease is the leading cause of morbidity and mortality 
in men and in women, as well, a cohort of patients with ACS was analysed (see 
below the study design, Figure 1) 
 
Figure 1 Study project 
 
 
 
 
                                                           4 Population and Methods 
 
  
 
  11 
 
4.2 Population 
4.2.1 Overall population 
In 2010, the population of ULSS 16 was 491,261 residents (255,026 females and 
236,235 males) and was evaluated anonymously based on demographic data, 
stratified  by gender and  five age groups (0-14, 15-44, 45-64, 65-79 and over 80).  
In 2008, the cohort of patients hospitalized after an ACS event was 1,204 out of 
483,042 (250,143 females and 232,899 males). 
 
4.2.2 ACS patients 
Patients admitted in Hospital after an ACS-event during the time period 1/1/2008-
31/12/2008 were analysed. ACS-events were classified by ICD IX-codes 
(International Statistical Classification of Diseases and related Health Problems). 
Data were collected from hospital database, hospital discharge forms, hospital 
pharmacies and local pharmacies evaluating: demographic data (age and gender), 
admission diagnosis (ACS), date of admission, discharge or transfer, previous 12 
months therapy (drug prescriptions), 6 months follow-up (drug prescription records), 
possible coronary interventions (classified as revascularized and non-revascularized 
patients) [see Table1].  
Table 1 Classification of Acute Coronary Syndrome 
Type ICD-IX Codes and description 
 
ACS-Non revascularized patients 
410    Acute Myocardial Infarction 
411    Other acute and subacute forms of ischemic heart disease 
         (only main diagnosis)   
 
 
 
 
ACS-Revascularized patients 
410    Acute Myocardial Infarction 
411    Other acute and subacute forms of ischemic heart disease 
36.01 Single vessel percutaneous transluminal coronary angioplasty without   
mention of thrombolytic agent 
36.02 Single vessel percutaneous transluminal coronary angioplasty with mention  
of thrombolytic agent  
36.05 Multiple vessel percutaneous transluminal coronary angioplasty [PTCA] 
performed during the same operation, with or without mention of  thrombolytic 
agent 
36.06 Insertion of non-drug-eluting coronary artery stent. 
          (only main diagnosis) 
 
Heart failure 
428    Heart failure          (only main diagnosis) 
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4.3 Medication 
Drugs that were considered in the present study were: Antiinfectives (ATC J) for 
systemic use Tetracyclines (J01A), Penicillins (J01C), Beta lactam antibiotics 
(J01D), Macrolides and Lincosamides (J01F), Quinolone antibacterials (J01M), 
Antimycotics for systemic use and Antiparasitic products (J02A); Gastro-intestinal 
drugs (ATC A, Anti-acids A02A, Anti-ulcer drugs A02B, drugs of Biliar Therapy 
A05A, Intestinal Antibiotics A07A); Calcium  & drugs affecting bone structure and 
mineralization (A12A); Potassium (A12B); Iron preparations (B03); Vitamin B12 and 
Folic acid (B03B); Anti-inflammatory and Anti-rheumatic products Non steroids 
(M01A); other Analgesics and Anti-pyretics (N02B); Opioids (N02A); Anti-migraine 
drugs (N02C); Antiepileptic drugs (N03A); Anti-parkinson drugs (N04A); 
Antipsychotic drugs (N05A); Antidepressant drugs (N06A); Corticosteroids (D07A); 
Thyroid and Anti thyroid drugs (H03); Anti-glaucoma preparations and Miotics 
(S01E); Antidiabetics (A10, Insulin therapy and Oral hypoglicemics);  Anti-acne & 
Psoriasis drugs (D10B); Antigout preparations (M04A); Adrenergics, Inhalants; other 
Systemic drugs for Obstructive airway disease (R03), Dopaminergic Agents; other 
drugs for Obstructive Airway Diseases, Inhalants (N04); Antihistamines for systemic 
use, Antiadrenergic agents, centrally acting drugs (R06).  
These are all cardiovascular medications with ATC C & A: Glycosides (C01A); 
Antiarithmics I and III class (C01B); Vasodilators used in cardiac diseases (C01D);  
Diuretics (low ceiling diuretics, Thiazides and low ceiling diuretics excluding 
Thiazides, high ceiling, Potassium-sparing agents, C03); Beta blockers (C07);  
Selective Calcium Channel Blockers With Mainly Vascular Effects and with direct 
cardiac effect (C08); Ace Inhibitors, Plain and ACE inhibitors, combinations; 
Angiotensin II Antagonists, Plain and Combinations (C09); Anti-thrombotic agents 
(B01A, B01B); HMG-CoA Reductase inhibitors Simvastatin and Ezetemibe, Fibrates 
(C10A). 
 
4.3 Calculation of therapy adherence 
The population on average gets a certain treatment daily. 
The numbers of DDDs per inhabitant per year, gives an estimate of the number of 
days for which each inhabitant is on average treated annually.  
                                                           4 Population and Methods 
 
  
 
  13 
 
 
The WHO's definition is: "The DDD is the assumed average maintenance dose per 
day for a drug used for its main indication in adults." 
Drug usage (DDDs)= Items issued x Amount of drug per item/DDD 
 Adherence to antiaggregation therapy (over six months) was analysed using 
Defined Daily Doses DDDs. Patients were treated with one antiaggregant with a 
dosage of 150mg/day (Aspirin/ Thienopyridine). Some were treated with a dual-
antiaggregation with a dosage of 300mg/day. Male and female patients were 
classified in 4 age groups for a better study comparison in: 15-44, 45-64, 65-79 and 
≥ 80 years old. Patients transferred from a hospital to the other were excluded. 
 
4.4 Statistical analysis 
Data stratification was processed using Microsoft Access and the calculation of sum, 
mean, standard deviation, ratios using Microsoft Excel 2003. Results were reported 
as odds ratios of prescriptions dispensed to males and females with 95% confidence 
intervals (OR is a measure of association between an exposure and an outcome 
most commonly used in case-control studies) to report the number of individuals that 
were prescribed at least one medication. A ratio of 1 indicates there was equal 
prescription of drug to males and females. A ratio >1, more medications were 
prescribed to males, and a ratio <1indicates prescribed medications in favour for 
women.  DDDs (Defined Daily Dose) were analysed to screen gender difference in 
adherence to therapies. Forest plots were used to illustrate gender/age differences 
in adherence and intervention analysis.  Wilcoxon test was used to verify the 
significance of the intervention analysis. Statistical analysis was performed using R-
project software version 2.15.1 for Windows (GNU project). Descriptive statistic 
included mean and standard deviation for normally distributed variables and median 
and interquartile range (IQR) for nonparametric variables. Study groups were 
compared using χ2 or Fisher’s exact test for categorical variables, the Student’s t-
test for normally distributed continuous variables and the Wilcoxon rank-sum test for 
nonparametric variables. The Kaplan Meier survival curves were performed using R-
project a statistical computing and graphics program, significance was verified using 
the Shapiro test. 
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5 Results and Discussion 
 
5.1 Dispensed medications to males and females stratified by ATC  
Of the 491,261 included subjects, 255,026 were females and 236,235 males. 
Females were more likely to receive prescriptions of most of Chemical therapeutic 
subgroups, e.g. antiulcer drugs (OR=0.80, 95% confidence interval [CI] 0.74-0.86), 
antibiotics as for tetracyclines (OR=0.91 95% CI 0.85-0.93) and penicillins (OR=0.90 
in the 95% CI 0.83-0.94), anti migraine products (OR 0.34 95% CI 0.0.31-0.36), 
antipsychotics (OR=0.86, 95% CI 0.81-0.90), antidepressants (OR=0.44, 95% CI 
0.40-0.52) diuretics (OR=0.72, 95% CI 0.66-0.80). On the other hand, males were 
more likely to be treated with antidiabetic drugs, including insulin (OR= 1.24 95% CI 
1.21-1.30) and oral hypoglycemics (OR=1.37 95% CI 1.33-1.40), with antithrombotic 
agents (OR=1.16 95% CI 1.14-1.20), betablockers (OR=1.15 95% CI 1.10-1.20), 
ACE-inhibitors (OR=1.25 95% CI 1.20-1.30). Moreover, for ACE-inhibitors a larger 
difference between males and females was noticed in the 15-44 years old group, 
decreasing with aging.  
On the whole, males were more likely to receive cardiovascular medications. 
Females were medication dispensed in most of ATC subgroups than males. Results 
were given as odds ratio (OR) to compare the two population groups, males and 
females. An OR<1, is indicative for a higher proportion of treated females, a ratio >1 
is indicative of higher dispensing to males. Medications with a prevalent use in 
females were: Anti-acids; Anti-ulcer drugs; drugs of Biliar Therapy; Intestinal 
Antibiotics; Calcium & drugs affecting bone structure and mineralization; Potassium; 
Iron preparations; Vitamin B12 and Folic acid; Antiadrenergic agents, centrally 
acting drugs; Diuretics; Potassium-sparing agents; Beta blockers and other 
Diuretics; Angiotensin II Antagonists, Combinations; Corticosteroids; Thyroid and 
Anti thyroid drugs, Antiinfectives for systemic use as Tetracyclines, Penicillins, Beta 
lactam antibiotics, Macrolides and Lincosamides, Quinolone antibacterials, 
Antimycotics for systemic use, Anti-inflammatory and Anti-rheumatic products, Non 
steroids; other Analgesics and Anti-pyretics; Opioids; Anti-migraine drugs; 
Antiepileptic drugs; Anti-parkinson drugs; Antipsychotic drugs; Antidepressant 
drugs; Anti-dementia drugs; agents against Amoebiasis and other Protozoal 
diseases; Anti-malarial drugs; agents against Leishmaniasis and Trypanosomiasis; 
Anti-glaucoma preparations and Miotics. Males were dispensed mostly with: Insulin 
  
  
 
 15 
 
therapy and Oral hypoglicemics; Anti-thrombotic agents; Glycosides; Vasodilators 
used in cardiac diseases; Antiadrenergic Agents, Peripherally Acting drugs; 
Selective Calcium Channel Blockers With Mainly Vascular Effects; Ace Inhibitors, 
Plain; Lipid Modifying Agents, Plain; Anti-acne & Psoriasis drugs, Antigout 
preparations; Adrenergics, Inhalants; other Systemic drugs for Obstructive airway 
disease. There was no difference in the number of treated males and females for 
those therapeutic subgroups: Antiarithmics I and III class; ACE inhibitors, 
combinations; Dopaminergic Agents; other drugs for Obstructive Airway Diseases, 
Inhalants; Antihistamines for systemic use.    
From 58  ATC subgroups,  of our interest, 13 were dispensed mostly in males, 5 had 
no gender difference in dispensing and all the other were dispensed mostly in 
females. This first overview showed that females were more treated than males. 
Anti-infectives are the most dispensed drugs, especially to women of all age groups, 
excluding 0-9 years (Macy, 2009). From our ATC groups, Penicillines were the most 
dispensed antibiotics, followed by Macrolides, Lincosamides, Quinolones, 
Betalactams and last Tetracyclines. During 2010, approximately 46% of women and 
about 39% of men were prescribed at least one antibiotic prescription. Frequently, 
antibiotics cause adverse reactions, e.g. Penicillines give side effects as hyper 
sensibility, especially in females over 80, or allergies most frequently in males under 
9 years old; Tetracyclines can induce the immunologic reaction Lupus Eritematosus 
in females (Minocicline); Meflochine, an antimalarial agent gives Central Nervous 
System side effects as sleep disorders, depression, epileptic crisis much more in 
females than males due to a different drug distribution, because it is known that 
females have a higher emetic cerebral flux. 
After Anti-bacterials, the Analgesics and Anti-inflammatory agents were the most 
dispensed drugs, especially in females. This could be an explanation of more 
Adverse Drug Reactions  in females as compared to males (Zopf, 2009). 
A large number of prescriptions for non steroidal inflammatory drugs, NSAIDs 
(M01), muscle relaxants (M03B), opioids (N02A), other analgesics (N02B) and anti 
migraine products (N02C) were prescribed in favour of women. 
 Over the Counter (OTC) pain relieving drugs and medications dispensed without a 
prescription were not included in this survey as they are not subsidized from the 
SSN (National Health Care). 
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Females have more chronic pain conditions. Most common diagnosed pain 
symptoms in females are chronic musculoskeletal pain, followed by 
arthritis/osteoarthritis, back pain, headache, migraine, unspecified pain, 
malignancies. The prescribing rates increased with patients’ age, especially over 70 
years old patients. There is a high proportion of elderly women taking these drugs 
due to the increased prevalence of arthritis/osteoarthritis. Females experience a 
lower pain tolerance and higher subjective pain ratings than males another reason 
of a more frequent administration of these drugs by females (Weisenfeld-Hallin Z, 
2005). 
Antidepressanst, Antidementia Agents, Antipsychotics and Anticonvulsants were all 
medicines with odds ratio<1, indicating a higher proportion of treated females than 
males. There was no difference in treated patients with the Dopaminergic agents. 
Antidepressants were the most used medicines in patients with mental health 
problems. 3.74% of the studied male population was treated at least once with 
antidepressants vs 8.09% of female patients suggesting that depression occurs in 
females more commonly than in males (2:1). This suggests that women are more 
prone to depression, they also report greater fear and are more likely to develop 
anxiety disorders than men (McLean, 2009). 
Epidemiological studies of different nations suggested that females are more likely 
to be treated with antidepressants, antipsychotics, antidementia agents, but no 
significant sex-related difference of therapy was stressed for Dopaminergic and 
Cholinergic agents (Statistics: Norway 2008, Wettermark, 2007 Sweden, US).   
Gastrointestinal drugs: Antiacids and Antiulcer drugs: these drugs were prescribed 
more to females than to males. Antiacids are used  in case of indigestion, heartburn, 
gastritis, and gastroesophageal reflux disease (GERD). Females display less 
physiologic episodes of gastroesophageal reflux than males, but symptoms are 
tolerated better by males. Quality of life is significantly worse for women with GERD 
(Lippmann, 2009).  Females report more intense abdominal pain when exposed to 
the same stimulus as males (Labus, 2008). This could be an explanation why they 
seek care to physicians for heartburn more than men.  
Another difference in visiting a physician has been reported with proton pump 
inhibitors for individuals with GERD conditions. Antiulcer drugs are prescribed for 
gastric or duodenal ulcer, gastro-esophageal reflux, and co-prescribed with NSAIDs. 
Comparing treatment of patients with NSAIDs and treatment with COX-2 inhibitors 
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would suggest that the second group of treated patients use less antiulcer drugs 
than the first group, but when adjusted for age, gender and number of prescriptions, 
patients in the COX-2 inhibitor group were still co-prescribed anti-peptic ulcer drugs 
more frequently than patients prescribed nonselective NSAIDs). These drugs were 
one of the most dispensed (13.18% M vs. 16.78%F).  In UK it is reported that 
antiulcer drugs made up 6.1% of all prescriptions dispensed and are the second 
most expensive group of drugs to the government (Teeling, 2004). 
Antiasthma drugs: It was noticed a gender difference in Antiasthma drugs utilisation 
for the Adrenergic Inhalants and other antiasthmatic for systemic use. Antiasthma 
drugs were dispensed to both male and female patients but with a higher dispensing 
to male patients. There was no significant gender-related difference in prescribed 
antihystamines for systemic use and other drugs for obstructive airway disease, 
inhalants.  
According to literature in childhood males are more prone to get asthma or 
asthmatic symptoms, but there is a switch in adulthood with a major occurrence of 
asthma among women. This suggested a role for estrogen and progesterone in 
asthma incidence. Female sex is an important risk factor. Male sex was associated 
with a significantly increased risk of death and with a significantly increased risk of 
re-hospitalisation for obstructive airways disease. Mean survival and time to 
rehospitalisation for obstructive airways disease are significantly better for female 
patients (Gonzalez, 2010).  
Females visit the emergency department for asthma more frequently than males do 
(Watson, 2003) and are more likely to report asthma attacks. Environmental 
exposures such as pollution, passive smoking are risk factors. Indoors activity as 
cooking with gas has been shown to be associated with respiratory symptoms and a 
small lung reduction another risk factor especially for women. It is well known that 
smoke causes problems to the respiratory tract (without mentioning all the other 
harmful risks). Smokers are undertreated with inhalants (Gonzalez, 2010). In our 
case adrenergic inhalants were more dispensed to males and for the other inhalants 
there was no difference in dispensing. Could this be due to the increased number of 
young female smokers? Another hypothesis could be that physicians prescribe to 
females more glucocorticoids than other antiasthma drugs especially for chronic 
asthma. Interaction between gender and asthma should be more studied and further 
examined. Generally, different international studies report unequal treatment 
between men and women (Anthony, 2008 & Loikas, 2013) 
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Table 2. Odds Ratios  
for medications 
classified by ATC.  
Red reported 
medications are  
indicative of a larger 
number of treated 
females OR<1. Blue 
reported medications 
are indicative of a 
larger number of 
treated   males, OR>1 
and grey reported 
medicationsn show 
equal in drug 
dispensation to males 
and females. Analysis 
has been done in 
patients who received 
at least one 
prescription of the 
reported drugs. 
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5.2 Gender differences in cardiovascular therapies 
5.2.1 General overview  
A major difference in prescribing was observed with cardiovascular medications. 
Although Cardio vascular Disease (CVD) is the number one cause of morbidity and 
mortality in both genders, males received this type of prescription adolescence more 
than females. For the age group 45-64 at least one Cardiovascular drug was 
dispensed to 32.2% of male patients and 26.5% to their female counterpart, 
increasing as patients get older (Figure 2). 
Males were more likely to receive prescriptions for cardiovascular medications, such 
as beta-blockers, ACE-inhibitors, antithrombotic agents (OR 1.16 95% CI 1.14-
1.20), and also more treated with antidiabetic drugs: insulin therapy (OR=1.24 95% 
CI 1.21-1.30) and with oral hypoglycaemics (OR=1.37 95% CI 1.33-1.40). Females 
were more exposed to diuretics (OR=0.72, 95% CI 0.66-0.80). A larger gender 
difference was noticed between 15-44 years old males and females and this 
difference decreased with aging, still remaining statistically significant.  Results 
show that in general men were more likely to be adherent to therapy as compared to  
women. Differences in adherence were more pronounced among patients under 80 
years of age. Young women were less adherent than the older ones. 
 
 
Figure 2 Odd Ratios Gender/Age difference in Cardiovascular treatment. 
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 It can be clearly seen that males of age 45-64, 65-79 (68.6% males vs. 66.6% 
females) and over 80 (75.1% males vs. 73.5% females) used cardiovascular drugs 
more than females. It is known that CVD affects men earlier in life and the incidence 
of heart disease increases in women with age (Melloni, 2010). 
Figure 3 shows that in general men of all age groups were more adherent to 
therapies than women. All the differences were statistically significant. Male patients 
were more adherent to ATC-C medicines than female patients with statistically 
significant outcome for the age groups of 15-44, 45-64, 65-79 and over 80. An 
increased adherence for both men and women was noticed for the age group 65-79 
and over 80. Differences in adherence between women and men were more 
pronounced among patients under their 80s. Some factors that affect patient’s 
adherence to medication are age, personal control such as living alone (Saito, 
2005), identity, emotional representations (Shiah-Lian, 2011), severity of illness, 
number of concomitant diseases, complexity of medication regimen (Granger, 
2008), depression (Bosworth, 2008), cognitive disorders (Stilley, 2004), health 
literacy and addictive behavior such as smoking or alcohol abuse (Evangelista, 
2009). Understanding all these factors that interfere with patient’s adherence could 
provide a better intervention. Women are less adherent comparing to their men 
peers to Cardiovascular medicines, thus gender is another major factor to be be 
considered and further studied. 
Figure 3 Gender/ Age difference in adherence to Cardovascular Disease 
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5.2.2 Insulin therapy and Oral Hypoglycaemics 
 
Diabetes and gender: For the insulin therapy and oral hypoglycaemics it was 
observed that females were less treated than males. The number of male patients 
that received at least one oral hypoglycaemic was 8,810 (3.73% of all the male 
treated population) vs. 7,224 of females (2.83% of all female treated population) with 
an odds ratio of 1.3 and confidence interval 95% CI=1.3-1.4.  On the other hand 
there were 2,981 (1.26%) males vs. 2,630 (1.03%) females receiving at least one 
medicine of the insulin therapy and an odds ratio of 1.2, 95%CI= 1.2-1.3. 
It is known that women with diabetes and hyperlipidemia receive a less aggressive 
therapy especially in the young age (Vilamananda, 2011). 5% of all diabetes are 
Type 1 Diabetes (T1DM). In some studies it was noticed a different incidence on 
diabetes related to age and gender. Under 15 years of age, men have a higher 
incidence rate: 23/100,000 male vs. 4.5/100,000 women and for the age group 15-
40 years: still 3:2 male excess was noticed (Gale, 2001) wondering if T1DM is 
genetic, sex, gender or age dependent. Women and men show slightly different 
incidence rates of diabetes mellitus, T2DM. Prevalence increases dramatically all 
over the world and is accompanied by a parallel rise of obesity. Diabetic men and 
women differ in the prevalence of pre-diabetes, diabetic complications, adherence to 
recommendations regarding lifestyle and drug therapy (Carstensen, 2008) . 
 In some studies of drug administration usually men were prescribed Metformin and 
Glitazone at a younger age, women instead were prescribed Acarbose over 55 
years because Rosiglitazone was found to increase the risk for bone fracture 
(Kautzky-Willer, 2009). There are some risk factors influencing the incidence of 
T2DM as ethnicity, family history (GDM=gestational diabetes mellitus), obesity 
(visceral).  In Africa, Japan and other less or more developed countries the 
incidence of Diabetes is lower. 
The increase in incidence of diabetes in developing countries follows the trend of 
urbanization and lifestyle changes, perhaps most importantly a "Western-style" diet. 
The World Health Organization (WHO) suggested that obesity accounts for 80% of 
diabetes. Abdominal obesity increases mortality (+33%M, 28% F).  
Visceral adiposity, fasting glucose concentration of >110mg/dl and impaired glucose 
tolerance(>risk in women), blood pressure of >130/85 mmHg and atherogenic lipid 
profile are all risk factors that impair myocardial metabolism more severely in 
women than in men (Regitz-Zagrosek, 2007).  Men and women with similar amounts 
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of liver fat do not exhibit sex-differences in insulin resistance. (Westerbacke, 2004). 
Liver fat strongly increases when glycaemia and glucose tolerance deteriorate and 
this depends on age but not on sex (Kantartzis, 2010). Pre-diabetic and diabetic 
women are at much higher risk for vascular disease than diabetic men. In the fertile 
age between 20 and 35 years of age, the incidence rate for women is twice larger 
than the one for men of the same age (Carstensen, 2008). Over 45 years, men have 
in general a higher risk of developing T2DM at younger age (Rathmann, 2009). 
Women show glucose intolerance more often at all ages and have a slightly higher 
prevalence of T2DM possibly caused by a prolonged gut glucose time (Anderwald, 
2011) and a lower height, less physical activity, socioeconomic status, hormones 
fluctuation (female: high testosterone; low plasma SHBG more prone to diabetes; 
male: low testosterone, erectile dysfunction and diabetes). Endogenous hormones 
may influence insulin sensitivity via their effects on adiposity. Testosterone is 
inversely associated with adiposity in men, but positively associated with adiposity in 
women. Clinical trials show that androgen deprivation increases adiposity and 
insulin resistance in men, while testosterone therapy decreases adiposity and 
improves insulin sensitivity. In women androgen therapy increases adiposity and 
antiandrogen therapy decreases adiposity (Ding, 2006). Although men have higher 
risk factors, progression rate is similar to women. Diabetes is a risk factor by itself 
leading to greater increase of cardiovascular disorders. Women with diabetes 
compared with those without are suffering from cardiovascular disease twice as 
common, they are four times as likely to be hospitalized, but less likely to be treated 
than men (Regitz-Zagrosek, 2007). 
 
 
 
 
Figure 4 Gender/Age difference in patients treated with insulin therapy 
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Figure 5 Gender/Age difference in patients treated with oral-hypoglycaemics. 
 
Men were more likely to be treated with antidiabetic drugs, including insulin (OR= 
1.24 95% CI 1.21-1.30) and oral hypoglycaemics (OR=1.37 95% CI 1.33-1.40). 
 
5.2.3 Beta-blockers, Diuretics, ACE-inhibitors, Lypid Modifying Agents 
Beta-blockers: For all age groups, beta-blockers were more prescribed among 
males than females with significant OR-result. Men were more treated with 
betablockers (OR=1.15 95% CI 1.10-1.20) than women.  
 
 
Figure 6 Gender/Age difference in patients treated with Betablockers 
 
 
Diuretics: Women administered more diuretics (OR=0.72, 95% CI 0.66-0.80). 
Diuretics are used especially on monotherapy for hypertension in women and in the 
elderly, usually causing adverse drug reaction as vertigo and osteoporosis for both 
genders (Lim, 2009). 
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The use of thiazides is associated in some patients with erectile dysfunction, even 
when the dose is kept as low as possible, thus males should be less exposed to 
those medicines, but no gender difference in prescription was noticed. Furosemide, 
a high ceiling diuretic is associated with a major mortality in women as compared to 
men with heart failure (Cohen, 2004).  Hypopotassemia caused by diuretics is more 
frequent in females. This would be the reason of a higher dispensation of Potassium 
sparing diuretics to women. Some gender differences in adherence were observed 
for the high ceiling diuretics and potassium sparing diuretics. 
 
 
 
Figure 7 Gender/Age difference in patients treated with diuretics. 
 
ACE-inhibitors (OR=1.25 95% CI 1.20-1.30): In the studied population on 
monotherapy with ACE-inhibitors, women were less likely than men to be prescribed 
an angiotensin converting enzyme for all groups of age. Although older women were 
prescribed more ACE-inhibitors, than the young one, men were still more prescribed 
with ACE-inhibitors (Figure 8). The question of whether ACE-inhibitors have a more 
favorable impact for men than for women cannot be a valid explanation on the basis 
of the small proportion of women included in ACE-inhibitors studies (Jochmann, 
2005). A larger difference in ACE-inhibitors use between males and females in the 
15-44 years group was noticed, decreasing with aging, but still the difference 
remained statistically significant.  
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Figure 8 Gender/Age difference in patients treated with ACE-inhibitors. 
 
Lypid Modifying Agents (OR= 1.53 95% CI 1.48-1.59): Pharmacokinetic gender-
specific differences with respect to statins are slight. Primary and secondary 
prevention of cardiovascular disease studies have revealed beneficial effects for 
both genders, but with a minor use in women than in men (Jochmann, 2006). Anti 
hyperlipidemics were prescribed less frequently in the age groups 45-64. In the age 
groups 65-79 there was a higher dispensing. In literature the lipid lowering therapy is 
associated with better outcomes for postmenopausal women. Substantially women 
have been undertreated for hyperlipidemia (Figure 9). 
 
 
 
Figure 9 Gender/Age difference in patients treated with lipid modifying agents. 
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5.3 Interventions in Acute Coronary Syndrome 
A total of 1204 (2.5‰) patients, 760 (3.26‰) males and 444 (0.92‰) females 
patients, with an ACS-event during 2008 admitted in Saint Anthony hospital were 
recruited in this study. 
Table 3 Demographic characteristics of enrolled patients 
 
  OR 95%IC         
MvsF 
Sex N ‰  
Male 760 3.26  
Female 444 0.92 1.7 (1.4-2)          M 
Total 1204 2.5  
Age in years (n) Male(n,‰) Female (n,‰)  
15-44   (18) 15 (1.57) 3 (0.03) 4.9 (1.6-15)        M 
45-64  (264) 220 (3.43) 44 (0.65) 5.3 (4.0-7.0)       M 
65-79  (506) 343 (10.81) 163 (4.11) 2.6 (2.2-3.2)       M 
≥80     (416) 182 (21.25) 234 (12.79) 0.8 (0.7-1.0)       NS 
Inhospital-mortality 
(Total 142=11.8%) 
72 70 1.0 (0.6-1.7)       NS 
Previous Hospitalization (2007) 
 
(Total 1204) 
66(5.48%) 26(2.16%)    1.5 (1.0-2.4)     NS
  
Re-hospitalization  until 31/12/2009 
Re-hospitalization until 30/06/2012 
(Total 1062) 
87(12.6%) 
165(24%) 
67(17.9%) 
120(32%) 
  0.7 (0.5-0.9)       F 
 
 0.7 (0.5-0.9)  F 
Revascularized vs. Non Revascularized  
Tot   M  F      M       F  OR 
1062    375     108      313         266  1.2 (1.0-1.6)            NS 
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The population was subdivided in four age classes. For each class a gender 
difference consideration was made. Overall men had higher prevalence to develop 
ACS. Considering age groups men up to79 years had a higher prevalence in 
developing ACS, while the over 80 population did not show any gender difference. 
Elderly women were larger in number, but comparing to the whole population, there 
was no significant difference between genders in ACS prevalence of this age group. 
Of the 1204 enrolled patients, 142 (11.8%) died in hospital before the follow-up 
without any gender difference in mortality rate, in accordance with other national and 
international studies (Osservatorio ARNO Cardiovascolare, 2012 & Akhter, 2009). 
Short term and long term re-hospitalization was analysed showing that women had 
higher relapse rates than men in both cases: in 2009, 17.9% women vs.12.6% men 
and on 30th June 2012 32% women vs. 24% men (Table 2).   
A previous 12 month analysis of those patients was done to verify hospitalization 
and pharmacological history to understand if patients received other therapies 
related to hypertension, diabetes, dislypidemia and depression that are all ACS risk 
factors. This analysis showed that no gender difference was noticed in 
hospitalization. A drug prescription analysis showed: 77% of women and 69% of 
men (OR=0.7 95%CI 0.5-0.9) had an antihypertensive medication and 17% of 
women and 8% of men (OR=0.4 95%CI 0.3-0.6) were treated at least once with an 
antidepressant. This may be potentially indicative of higher rates of hypertension 
and depression among ACS women. There was no difference in drug utilization for 
diabetes (21%M and F), nor for dyslipidemia treatment [37% M vs. 32% F, OR=1.3 
95%CI 1.0-1.6, NS-(not significant)]. Age group subdivision did not show significant 
difference in utilizations of these drugs between genders with the exception of a 
major antidepressant use among women of 65-79 years old (Table 4). Other studies 
confirm that women with ACS tend to have more cardiovascular risk factors such as 
diabetes, hypertension andì hypercholesterolemia and the possible explanation was 
that women in pre-menopause are protected from estrogens, but in post-menopause 
they start to loose hormone protection thus they present with ACS 10 years later 
than men and at this time they have a higher cardiovascular risk factor (Claassen, 
2012). First co-morbidity of ACS patients, seems to be depression especially in the 
female population and diabetes is present in their medical history in one fourth of the 
subject (Osservatorio ARNO Cardiovascolare, 2012).   
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Table 4 Previous 12 months pharmacological treatment as an ACS-risk factor predictor: gender/age based 
evaluation. 
 M (n) (%) F(n) (%) TOT   OR (95%CI) M vs. F 
Hypertension therapy         M F     
15-44 5 33% 2 67% 15 3 0,3(0-0,3) F 
45-64 111 50% 26 59% 220 44 0,7(0,4-1,4) NS 
65-79 271 79% 121 74% 343 163 1,3 (0,8-2) NS 
≥80 135 74% 193 82% 182 234 0,6 (0,4-1) NS 
TOT 522 69% 342 77% 760 444 0,7 (0,5-0,9) F 
Diabetes                 
15-44 2 13% 0 0% 15 3 0 NS 
45-64 30 14% 4 9% 220 44 1,6 (0,5-4,7) NS 
65-79 93 27% 35 21% 343 163 1,4 (0,9-2,1) NS 
≥80 31 17% 54 23% 182 234 0,7 (0,4-1,1) NS 
TOT 156 21% 93 21% 760 444 1 (0,7-1,3) NS 
Dyslipidemia treatment 
(C10A) 
                
15-44 4 27% 1 33% 15 3 0   
45-64 72 33% 12 27% 220 44 1,3 (0,6-2,7) NS 
65-79 144 42% 68 42% 343 163 1 (0,7-1,5) NS 
≥80 63 35% 61 26% 182 234 1,5 (1-2,3) NS 
TOT 283 37% 142 32% 760 444 1,3 (1-1,6) NS 
Depression (N06A)                 
15-44 0 0% 0 0% 15 3 0   
45-64 16 7% 6 14% 220 44 0,5 (0,2-1,3) NS 
65-79 21 6% 29 18% 343 163 0,3 (0,2-0,5) F 
≥80 23 13% 40 17% 182 234 0,7 (0,4-1,2) NS 
TOT 60 8% 75 17% 760 444 0,4 (0,3-0,6) F 
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After excluding patients that died in-hospital, further analysis was performed in 
1,062 ACS patients: 483 (40.1%) underwent revascularization and 579 (48.1%) 
were not revascularized. A general gender anlysis did not show any differences in 
interventions, but a further evaluation by age revealed major revascularization in the 
65-79 and ≥80 year old male populations (Figure 11). Median age of revascularized 
men was 67 years (interquartile range [IQR] 58-74 years old) and age of women 
was 72 (IQR 66-78 years old). Median age for the non-revascularized population 
was  men 75 years  (IQR 64-81), women 82 years  with IQR 75-88. 
Female patients are generally older and with more comorbities when diagnosed with 
an ACS and anatomically have smaller vessels, thus are less likely than male 
patients to undergo invasive evaluation and surgery intervention. Women have 
higher rates of bleeding complications, consistently seen in trials (Redberg, 2006).  
 
Figure 10 Gender/age difference in revascularized vs. non revascularized ACS patients  
An analysis of pharmacological therapy showed a total lack of anti-aggregants use 
in 191 (18%) patients during the first semester of follow up after the ACS event. 
Gender classification showed a larger number of untreated women 12.4%M vs. 28% 
F, OR=2.8 95%CI 2.1-3.8 p<0.01.  
  
  
 
 30 
 
The evaluation of antiaggregant use was done for revascularized and non-
revascularized patients. Female non-revascularized patients were larger in number 
than their male counterparts not receiving any antiaggregant 36%F vs. 20%M, 
OR=2.2 95%CI 1.5-3.2. Non-revascularized women were treated mostly with aspirin 
36%F vs. 35%M, OR=0.6 95%CI 0.4-0.9. On the other hand men were treated 
mostly with dual antiplatelet therapy (36%M vs. 20%F OR=1.8 95%CI 1.2-2.7). Most 
patients underwent revascularization. A gender difference was noticed in 
thienopyridines use between revascularized patients. Women were prescribed more 
thienopyridines than (men 9%F vs. 3%M, OR=0.3 95%CI 0.1-0.8) (Table 5). 
Table 5  Anti-aggregation therapy six months after ACS-event: gender based evaluation. 
 
  
M % F % TOT % OR (95%CI) p-value MvsF 
 No therapy 85 12.4% 106 28% 191 18% 2.8 (2.1-3.8) <0.01 F 
 Aspirin 217 31.5% 124 33% 341 32% 0.7 (0.5-0.9) <0.05 F 
 Thienopyridines 39 5.7% 31 8% 70 7% 0.5(0.3-0.9) <0.025 F 
 Dual antiplatelets 347 50.4% 113 30% 460 43% 1.9(1.4-2.5) <0.005 M 
 
 
Total therapy 
 
603 
 
87.60% 
 
268 
 
71.7% 
 
871 
 
82,02 
 
2.8 (2.1-3.8) 
   
M 
 
Revascularized patients were younger than the non revascularized ones for both 
genders. The median age of revascularized men is lower than that of women. This 
shows that physicians postpone females’revascularization and older non 
revascularized patients were still female patients. This confirms that women are less 
likely to be revascularized than men (Figure 12). The problem is that non 
revascularized patients were prescribed guideline-recomendation therapies less 
frequently than revascularized patient. Thus,  female patients seem to be the 
population  under greater risk (Sabouret, 2010) 
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Figure 11 Antiaggregant therapy of revascularized vs. non revascularized 
The Fisher’s exact test for count data confirmed that both for men and for women 
adherence to conservative therapy and invasive interventions reduces mortality 
(Table 6) 
Table 6 Mortality vs Adherence and vs Intervention: a gender difference analysis  
Mortality TOTAL M F 
Adherence OR 0.16 
95%CI 0.12-0.25 
OR 0.23 
95%CI 0.15-0.34 
OR 0.11 
95%CI 0.07-0.18 
Intervention OR 0.13 
95%CI 0.09-0.18 
OR 0.18 
95%CI 0.11-0.28 
OR 0.16 
95%CI 0.04-0.18 
 
 
 
 
Figure 12 Adherence analysis 
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Figure 12 and Table 7 reports a good adherence >=74% to antiplatelet therapies for 
both genders. A significant gender difference was detected in general for all 
antiplatelets use and especially in the aspirin use. An age related adherence 
difference was noticed in the very old population. Male patients over 80 years old 
were significantly more adherent than their female counterparts of 90%, OR=1.9 
95%CI 1.1-3.4. After antiplatelet subdivision in aspirin, thienopyridines and double 
antiagregation therapy, women were less adherent than men and especially less 
adherent than young men (total patients adherent to aspirin 92%M vs. 82% F, 
OR=2.4 95%CI 1.2-4.6, and age 45-64 year old patient adherent to aspirin 95%M 
vs. 79% F, OR=5.0 95%CI 1.1-22.5). 
 
Table 7 Gender/Age difference between adherent to Antiaggregants and not adherent patients 
to Antiaggregants. 
ASA 
 ADHERENT NON ADHERENT TOT  OR (95%IC) M vs F 
 M % F % M % F % M F   
15-44 2 100% 1 100% 0 0% 0 0% 2 1 Ns Ns 
45-64 73 95% 11 79% 4 5% 3 21% 77 14 5 (1,1-22,5) M 
65-79 87 92% 50 98% 8 8% 1 2% 95 51 0,2 (0,0-1,5) Ns 
>=80 37 86% 40 69% 6 14% 18 31% 43 58 2,8 (1,0-7,6) Ns 
TOT 199 92% 102 82% 18 8% 22 18% 217 124 2,4 (1,2-4,6) M 
THIENOPYRIDINES 
15-44 0 0% 0 0% 0 0% 0 0% 0 0 _ _ 
45-64 6 100% 3 75% 0 0% 1 25% 6 4 _ _ 
65-79 21 84% 10 91% 4 16% 1 9% 25 11 0,5 (0,1-5,3) Ns 
>=80 7 88% 13 81% 1 13% 3 19% 8 16 1,6 (0,1-19,3) Ns 
TOT 34 87% 26 84% 5 13% 5 16% 39 31 1,3 (0,3-5,0) Ns 
DUAL ANTIPLATELETES 
15-44 9 82% 1 100% 2 18% 0 0% 11 1 _ _ 
45-64 95 79% 17 85% 25 21% 3 15% 120 20 0,7 (0,2-2,5) Ns 
65-79 131 76% 51 77% 41 24% 15 23% 172 66 0,9 (0,5-1,8) Ns 
>=80 30 68% 15 58% 14 32% 11 42% 44 26 1,6 (0,6-4,3) Ns 
TOT 265 76% 84 74% 82 24% 29 26% 347 113 1,1 (0,7-1,8) Ns 
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5.3.1 Survival of the general and ACS population  
 
Information to draw the survival curve was collected on 413,148 residents 
(198,704M and 214,444F). There was no gender difference in the survival in 55 
months of followup of the general population (Figure 13). 
 
 
Figure 13 Survival curve of general population since 1/01/2008 until 30/06/2012 (55 months of 
FU). 
 
A difference in survival was noticed when the overall population was subdivided in 
<80 years old and ≥80 (see Figure 14). In general women live longer and have a 
better survival than men. 
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Figure 14 Survival curves of the overall population (younger than 80 years old and the very old 
population, the over ≥80) 
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The Kaplan-Meier survival curve was performed to understand the survival to 55 
months post ACS event on 1,204 patients. A significant difference between genders 
of ACS patients was detected. Men survive longer than women. Accross two age 
groups: under and over 80 years old, this tendency of a higher survival between 
men is maintained. Of the under 80 years old group no difference beteween genders 
was detected (OR=1.3 95%CI 0.9-2.0). This disparity between men and women 
increased and became significant in the very old population (OR=1.7 95%CI 1.1-
2.5). Throughout the first year of follow-up no difference in mortality rate was 
reported. Very old women presented 70% higher risk mortality rate than men after 4 
years of follow-up.  
 
Figure 15 Survival curve of ACS population since 1/01/2008 until 30/06/2012 (55 months of FU). 
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Figure 16 Survival curves of the ACS population (younger than 80 years old and the very old 
population, the over ≥80) 
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This study enrolled a high proportion of patients with acute coronary syndromes and 
these results can be compared with other international ones. Women with ACS have 
an increased mortality risk (Figure 15). In a review this higher mortality is reported 
among young women and it disappears with age (Claassen, 2012), but in our case 
even old women have higher mortality risk than their men counterparts (Figure 16). 
In order to better confirm a worse outcome in women different studies report later 
arrival at the hospital, longer hospital stays (Hee Tae, 2011) higher rates of in-
hospital complications (Akheter, 2009), inadequacy of therapeutic management of 
especially non-revascularized patients (the female patient in our case). 
Standard treatment guidelines and educational interventions are important 
strategies to improve the quality of health care 
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6 Conclusions 
 
A limited number of studies have examined sex and age differences in overall 
therapies for the global population. Results of this study confirm that women 
especially over their 50s are the larger number of customer comparing to men. 
These data collected and statistically performed are a valuable source of information 
on the characteristics, treatment of the italian population for physicians and all 
people working in the Sanitary and should serve for continuing improvements in 
patients‘ quality of care and prevention. 
An importance has been given to cardiovascular therapies and especially to the 
acute coronary syndrome therapy management. Gender/age  bias were noticed.  
Despite our study and the international literature reporting bias in gender ACS 
management in favour of men, there are other studies that do not report such 
differences. However, standard treatment guidelines and educational interventions 
are required for an effective cardiac treatment modalities.  
A review of drug prescriptions and ACS management is warranted in Italy to ensure 
that female and male patients are receiving the adequate treatments to reduce 
mortality, morbidity thus providing a better health outcome. 
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